On Tuesday, an expert panel unanimously recommended that the US Food and Drug Administration approve the Pfizer Inc and BioNTech SE COVID-19 vaccine for children aged 5 to 11, stating that the vaccine’s advantages surpass the risks.
An approval for that age range would be a significant regulatory step toward inoculating nearly 28 million youngsters, the majority of whom would return to school for in-person learning .The vaccination could be accessible for children as early as next week.
